Recovery accelerated

General pain relief

In a clinical study of patients who underwent knee arthroscopy, those treated with VISCOSEAL® reported a significant reduction in pain, measured on the 100 mm visual analogue scale (VAS), compared with those who underwent the standard procedure with saline lavage only. The improvement was significant 1 week after surgery (p <0.01) and was maintained for at least 1 month.⁴¹

Post-surgery, VISCOSEAL® reduces pain on the VAS  compared to the standard procedure⁴¹  

Pain relief and functional improvement

VISCOSEAL® confers advantages over anaesthetic
(bupivacaine) 3-6 weeks after arthroscopy.⁴² In a
randomised study, patients undergoing arthroscopy
received 10 mL of bupivacaine 0.5% or VISCOSEAL®
following surgery. Patients who received VISCOSEAL®
had significantly less pain measured on the VAS,
required significantly less analgesia and had a
significant improvement in function demonstrated by
a larger decrease in WOMAC score (p ≤0.05) than
patients who received bupivacaine.

VISCOSEAL® reduces pain on weight bearing according to the 10cm VAS compared with bupivacaine⁴²

Post-arthroscopy, VISCOSEAL® reduces the need for analgesics compared with bupivacaine⁴²

Post-arthroscopy, VISCOSEAL® reduces the mean WOMAC score compared with bupivacaine⁴²

Reduction in joint swelling

In another study involving patients who underwent 
arthroscopic partial meniscectomy and joint lavage, 
there was markedly less  swelling in the joints of 
patients who received VISCOSEAL® (n = 20), compared 
with those who did not (n = 20). This reduction in the 
severity of swelling remained apparent at day 28.⁴³

VISCOSEAL® reduces postarthroscopic swelling compared with controls⁴³

Effective in aiding recovery

In the same study, patients treated with VISCOSEAL® 
were more satisfied with their treatment than patients 
who underwent standard arthroscopy. Patients rated
global efficacy over 1 month. At each time point, more 
patients in the VISCOSEAL® arm rated efficacy as 
optimum/good than in the control arm.⁴³

Following arthroscopy, the percentage of patients who rated global efficacy as optimum or good was higher among the VISCOSEAL® group than among the control group ⁴³